A comparison of lanreotide and octreotide LAR for treatment of acromegaly

Clinical Endocrinology

Volumn 51, Issue 3, 1999, Pages 275-280

  Turner, H E ^b   Vadivale, A ^b   Keenan, J ^b   Wass, J A H ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ACROMEGALY; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; STATISTICS, NONPARAMETRIC;

EID: 0038234332     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1999.00853.x     Document Type: Article

References (19)

1. Ahmed, A., ElSheikh, M., Schwobell, J., Page, R.C.L., Adams, C.B.T. & Wass, J.A.H. (1999) Outcome of trans-sphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocinology, 50, 561-567.
2. Al-Maskari, M., Gebbie, J. & Kendall-Taylor, P. (1996) The effect of a new slow-release, long-acting somatostain analogue, lanreotide, in acromegaly. Clinical Endocrinology, 45, 415-421.
3. Bates, A.S., Van't Hoff, W., Jones, J.M. & Clayton, R.M. (1993) An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine, 86, 293-299.
4. Caron, P., Morange-Romas, I., Cogne, M. & Jaquet, P. (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release Lanreotide. Journal of Clinical Endocrinology and Metabolism, 82, 18-22.
5. Davies, P.H., Stewart, S.E., Lancranjan, I., Sheppard, M.C. & Stewart, P.M. (1998) Long-term therapy with long-acting octreotide (Sandostatin LAR) for the management of acromegaly. Clinical Endocrinology, 48, 311-316.
6. Flgstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C. & Jervell, J. (1997) Sandostatin LAR, in acromegalic patients: long term treatment. Journal of Clinical Endocrinology and Metabolism, 82, 23-28.
7. Giusti, M., Gussoni, G., Cuttica, C.M. & Giordano, G. (1996) and the Italian Multicenter slow release Lanreotide study group Effectiveness and tolerability of slow release Lanreotide treatment in active acromegaly: six month report on an Italian Multicenter study. Journal of Clinical Endocrinology and Metabolism, 81, 2089-2097.
8. Lamberts, S.W.J. (1988) The role of somatostatin in the regulation of anterior pituitary hormones and the use of its analogues in the treatment of human pituitary tumours. Endocrine Reviews, 9, 417-436.
9. Lisset, C.A., Peacey, S.R., Laing, I., Tetlow, L., Davis, J.R.E. & Shalet, S.M. (1998) The outocome of surgery: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical Endocrinology, 49, 653-657.
10. Melmed, S. (1990) Acromegaly. New England Journal of Medicine, 322, 966-977.
11. Morange, I., De Boisvilliers, F., Chanson, P., Lucas, B., Dewailly, D., Catus, F., Thomas, F. & Jaquet, P. (1994) Slow release lanreotide treatment in aeromegalic patients previously normalised by Octreotide. Journal of Clinical Endocrinology and Metabolism, 79, 145-151.
12. Orme, S.M., McNally, R.J., Cartwright, R.A. & Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
13. Osman, I.S., James, R.A., Chatterjee, S., Mathias, D. & Kendall-Taylor, P. (1994) Factors dtermining the long-term outcome of surgery for acromegaly. Quarterly Jounal of Medicine, 87, 617-623.
14. Sheaves, R. (1994) Pituitary Irradiation for Acromegaly. In Treating Acromegaly (ed. J. A. H. Wass), pp. 103-109. Society for Endocrinology, Bristol.
15. Sheaves, R., Jenkins, P., Balckburn, P., Huneidi, A.H., Afshar, F., Medbak, S., Grossman, A.B., Besser, G.M. & Wass, J.A.H. (1996) Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clinical Endocrinology, 45, 407-413.
16. Stewart, P.M., Kane, K.F., Stewart, S.E., Lancranjan, I. & Sheppard, M.C. (1995) Depot Long-acting Somatostatin Analog (Sandostatin-LAR) is an effective treatment for Acromegaly. Journal of Clinical Endocrinology and Metabolism, 80, 3267-3272.
17. Swearingen, B., Barker, F.G., Katznelson, L., Biller, B.M.K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P.M. & Zervas, N.T. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Edocrinology and Metabolism, 83, 3419-3426.
18. Vance, M.L. & Harris, A.G. (1991) Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Archives of Internal Medicine, 151, 1573-1578.
19. Wass, J.A. (1997) Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. Journal of Endocrinology, 155(Suppl.), S57-58.